Concepta PLC Commercial update (5801O)
02 Giugno 2020 - 08:00AM
UK Regulatory
TIDMCPT
RNS Number : 5801O
Concepta PLC
02 June 2020
Concepta PLC
("Concepta" or the "Company")
Commercial update
Concepta PLC (AIM: CPT), the innovative UK personalised
healthcare company and developer of myLotus(R), the UK's most
accurate home-use fertility tracking and pregnancy self-testing
system, provides an update on the Company's readiness for wider
commercial roll-out.
Following the Board changes announced in October and November
last year, the Company has made substantial improvements to its
operational structure to best position the business to ensure the
commercial success of myLotus(R). Significant cost savings have
been achieved and manufacturing has been successfully outsourced,
allowing Company funds to be deployed towards digital marketing and
commercial sales efforts. Concepta has also secured funds, via a
recent Placing which raised GBP1.9m (gross), to support increased
commercial activities as the Company aims to increase consumer
awareness of its flagship self-test fertility monitor.
Since the announcement of the first myLotus birth in October
2019, Concepta has had the chance to share in the stories of over
26 women who have used myLotus to successfully conceive and give
birth, and have shared their news with Concepta. Whilst the Company
is still in the early stages of commercial roll-out, it continues
to build on listings on www.boots.com and Amazon. A repositioned
myLotus will emerge from June 2020 along with a fully optimised
digital campaign, and this will be followed by a new App which is
expected to be available for those using myLotus in Q4 2020.
The Company also announced an exclusive global licence with
Abingdon Health Limited ("Abingdon Health") for the use of its App
Dx IP for human pregnancy and fertility. App Dx uses cutting-edge
software to transform a smartphone into a powerful lateral flow
reader and unlocks the potential for Concepta customers to access
rapid test results, further information and connectivity with
supporting services at home. Feasibility work on the new product
has commenced and, subject to a successful development, it is
expected to be launch-ready in 2021.
Penny McCormick, Chief Executive Officer of Concepta plc,
commented:
"We have been working hard on the marketing effort for myLotus
this year so that we are ready to optimise our reach and connect
directly with our target end users. Our team has been strengthened
with the appointment of key marketing, digital and customer care
roles, and we are gearing up for a rollout in the second half of
2020. As awareness of our brand builds, we look forward to seeing
more pregnancies and births ahead, and most importantly, more women
engaging with their conception health, and a new emotionally
intelligent educational approach."
Concepta plc www.conceptaplc.com
P enny McCormick , Chief Executive via Walbrook PR
Officer
Maddy Kennedy, Chief Financial
Officer
SPARK Advisory Partners Limited Tel: +44 (0)20 3368 3550
(NOMAD)
Neil Baldwin
Novum Securities (Broker) Tel: +44 (0)20 7399 9400
Colin Rowbury
Walbrook PR Ltd (Media & Investor Tel: +44 (0)20 7933 8780 or concepta@walbrookpr.com
Relations)
Paul McManus Mob: +44(0)7980 541 893
About Concepta PLC ( www.conceptaplc.com )
Concepta PLC is an AIM-quoted pioneering UK healthcare company
that has developed a proprietary product, myLotus(R), targeted at
the personalized mobile health market with a primary focus on
hormone testing and increasing a woman's chances of naturally
getting pregnant and to provide insight to unexplained
infertility.
myLotus(R) is currently the only consumer product which allows
both quantitative and qualitative home (self-test) test measurement
of a woman's personal luteinizing hormone (LH) during ovulation and
human chorionic gonadotropin (hCG) hormone level during pregnancy,
facilitating higher conception rates and early diagnosis of
fertility issues. The proposition of myLotus(R) is to empower women
to better understand their hormone levels and menstrual cycle and
help women conceive naturally by identifying their window of
fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus(R)
and has launched its first product in the UK. The Company is
preparing plans to roll-out across the core EU countries in
2020.
myLotus(R) is expected to be beneficial to users who have been
unable to conceive after 6 months of trying. This highly motivated
target group of women won't typically be offered medical
intervention until after 12 months of unsuccessfully trying to
conceive, with IVF not usually offered until after two years of
trying to conceive. Research indicates couples start to take
positive action ahead of this time typically with little medical
support to help them do so.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDEADKFEDXEEFA
(END) Dow Jones Newswires
June 02, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Myhealthchecked (LSE:MHC)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Myhealthchecked (LSE:MHC)
Storico
Da Mar 2023 a Mar 2024